BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20858724)

  • 1. Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction.
    Okui T; Shimo T; Fukazawa T; Kurio N; Hassan NM; Honami T; Takaoka M; Naomoto Y; Sasaki A
    Mol Cancer Ther; 2010 Nov; 9(11):2960-9. PubMed ID: 20858724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of different osteoclast phenotypes in the progression of bone invasion by oral squamous cell carcinoma.
    Quan J; Hou Y; Long W; Ye S; Wang Z
    Oncol Rep; 2018 Mar; 39(3):1043-1051. PubMed ID: 29286135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sonic hedgehog signaling promotes growth of oral squamous cell carcinoma cells associated with bone destruction.
    Honami T; Shimo T; Okui T; Kurio N; Hassan NM; Iwamoto M; Sasaki A
    Oral Oncol; 2012 Jan; 48(1):49-55. PubMed ID: 21945071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL2 synthesized by oral squamous cell carcinoma is involved in cancer-associated bone destruction.
    Oue E; Lee JW; Sakamoto K; Iimura T; Aoki K; Kayamori K; Michi Y; Yamashiro M; Harada K; Amagasa T; Yamaguchi A
    Biochem Biophys Res Commun; 2012 Aug; 424(3):456-61. PubMed ID: 22771802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor-β synthesized by stromal cells and cancer cells participates in bone resorption induced by oral squamous cell carcinoma.
    Nakamura R; Kayamori K; Oue E; Sakamoto K; Harada K; Yamaguchi A
    Biochem Biophys Res Commun; 2015 Mar; 458(4):777-82. PubMed ID: 25681764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Neurokinin 3 Receptor Signaling in Oral Squamous Cell Carcinoma.
    Obata K; Shimo T; Okui T; Matsumoto K; Takada H; Takabatake K; Kunisada Y; Ibaragi S; Yoshioka N; Kishimoto K; Nagatsuka H; Sasaki A
    Anticancer Res; 2017 Nov; 37(11):6119-6123. PubMed ID: 29061792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ammonium tetrathiomolybdate enhances the antitumor effects of cetuximab via the suppression of osteoclastogenesis in head and neck squamous carcinoma.
    Morisawa A; Okui T; Shimo T; Ibaragi S; Okusha Y; Ono M; Nguyen TTH; Hassan NMM; Sasaki A
    Int J Oncol; 2018 Mar; 52(3):989-999. PubMed ID: 29328370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.
    Okui T; Shimo T; Hassan NM; Fukazawa T; Kurio N; Takaoka M; Naomoto Y; Sasaki A
    Anticancer Res; 2011 Apr; 31(4):1197-204. PubMed ID: 21508365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of NF-κB suppresses bone invasion by oral squamous cell carcinoma in vivo.
    Furuta H; Osawa K; Shin M; Ishikawa A; Matsuo K; Khan M; Aoki K; Ohya K; Okamoto M; Tominaga K; Takahashi T; Nakanishi O; Jimi E
    Int J Cancer; 2012 Sep; 131(5):E625-35. PubMed ID: 22262470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
    Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
    Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANKL synthesized by both stromal cells and cancer cells plays a crucial role in osteoclastic bone resorption induced by oral cancer.
    Sato K; Lee JW; Sakamoto K; Iimura T; Kayamori K; Yasuda H; Shindoh M; Ito M; Omura K; Yamaguchi A
    Am J Pathol; 2013 May; 182(5):1890-9. PubMed ID: 23499553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and comparative effectiveness of sirolimus as an anticancer drug.
    Hu M; Ekshyyan O; Herman Ferdinandez L; Rong X; Caldito G; Nathan CO
    Laryngoscope; 2011 May; 121(5):978-82. PubMed ID: 21520111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
    Harada K; Supriatno ; Yoshida H; Sato M
    Int J Oncol; 2005 Dec; 27(6):1489-97. PubMed ID: 16273203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
    Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
    J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL.
    Tohyama R; Kayamori K; Sato K; Hamagaki M; Sakamoto K; Yasuda H; Yamaguchi A
    J Oral Pathol Med; 2016 May; 45(5):356-64. PubMed ID: 26859422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice.
    Cui N; Nomura T; Noma H; Yokoo K; Takagi R; Hashimoto S; Okamoto M; Sato M; Yu G; Guo C; Shibahala T
    Clin Cancer Res; 2005 Apr; 11(7):2713-9. PubMed ID: 15814653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer.
    Yoneda T; Williams P; Rhine C; Boyce BF; Dunstan C; Mundy GR
    Cancer Res; 1995 May; 55(9):1989-93. PubMed ID: 7728770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.